Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.

Autor: Piver RN; Department of Obstetrics and Gynecology, The Ohio State University Medical Center, Columbus, OH, USA., Wagner VM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Levine MD; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Backes FJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Chambers LJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Cohn DE; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Copeland LJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Cosgrove CM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Nagel CI; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., O'Malley DM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA., Bixel KL; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA.

Publikováno v: Gynecologic oncology reports [Gynecol Oncol Rep] 2023 Feb 28; Vol. 46, pp. 101156. Date of Electronic Publication: 2023 Feb 28 (Print Publication: 2023).

Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptor.

Autor: Beswick PJ; Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex CM19 5AW, UK., Billinton A, Chambers LJ, Dean DK, Fonfria E, Gleave RJ, Medhurst SJ, Michel AD, Moses AP, Patel S, Roman SA, Roomans S, Senger S, Stevens AJ, Walter DS

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2010 Aug 01; Vol. 20 (15), pp. 4653-6. Date of Electronic Publication: 2010 Jun 08.

Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.

Autor: Swarbrick ME; Pain and Neuroexcitability Discovery Performance Unit, Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK., Beswick PJ, Gleave RJ, Green RH, Bingham S, Bountra C, Carter MC, Chambers LJ, Chessell IP, Clayton NM, Collins SD, Corfield JA, Hartley CD, Kleanthous S, Lambeth PF, Lucas FS, Mathews N, Naylor A, Page LW, Payne JJ, Pegg NA, Price HS, Skidmore J, Stevens AJ, Stocker R, Stratton SC, Stuart AJ, Wiseman JO

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2009 Aug 01; Vol. 19 (15), pp. 4504-8. Date of Electronic Publication: 2009 Feb 26.

Negative and positive allosteric modulators of the P2X(7) receptor.

Autor: Michel AD; Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited, Harlow, Essex, UK. anton.d.michel@gsk.com, Chambers LJ, Walter DS

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2008 Feb; Vol. 153 (4), pp. 737-50. Date of Electronic Publication: 2007 Dec 10.